BioSpace News Archive

LEO Pharma Inc. announced the availability of the Adtralza® pre-filled pen in Canada. Adtralza is currently indicated in patients 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.1 Prior to the introduction of the pre-filled pen, Adtralza was only available in a 1 mL pre-filled syringe.

A team of investigators at City of Hope funded by the Prostate Cancer Foundation reports that patients with advanced prostate cancer can be safely treated with chimeric antigen receptor T cell therapy.

Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning platform with multiple clinical-stage drug programs, announced that the Japan Patent Office has issued a Certificate of Patent for patent application no. 2021-513267 / registration no. 7489966 directed to Lantern Pharma’s drug candidate LP-284.

Science 37 Holdings, Inc., a leader in enhancing patient access to clinical trials, announced the final enrollment figures from its 20-month engagement with a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders.

Quoin Pharmaceuticals Ltd., a specialty pharmaceutical company focused on rare and orphan diseases, announced that it has signed a research agreement with The School of Pharmacy at University College Cork, Ireland.

Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that it will host Part I of its virtual investor educational series on Thursday, June 20, 2024, at 8:00 AM ET.

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”),VERSATILE-002 is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a data update from its ongoing VERSATILE-002 Phase 2 clinical trial.

Fulcrum Therapeutics, Inc.® announced upcoming presentations to be made at the 31st Annual FSHD Society International Research Congress being held June 13-14, 2024 in Denver, Colorado, including an abstract outlining the baseline characteristics of patients enrolled in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy.

Triveni Bio Inc. announced that Bhaskar Srivastava, M.D., Ph.D., has joined the company as Chief Medical Officer.

DiamiR Biosciences announced that the company’s co-founder Dr. Kira Sheinerman will present at the 2024 International Rett Syndrome Foundation Rett Syndrome Scientific Meeting, taking place June 18-19, 2024, in Westminster, CO.